Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness
Publisher DOI
PubMed ID
20964261
Abstract
Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD), but not all patients benefit from this therapy. We used data from the Swiss Inflammatory Bowel Disease Cohort Study and predefined appropriateness criteria to examine the appropriateness of use of infliximab (IFX) in CD patients.
Date Issued
2010
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Juillerat, Pascal | |
Pittet, Valérie | |
Vader, John-Paul | |
Burnand, Bernard | |
Gonvers, Jean-Jacques | |
de Saussure, Philippe | |
Mottet, Christian | |
Rogler, Gerhard | |
Sagmeister, Markus | |
Felley, Christian | |
Michetti, Pierre | |
Froehlich, Florian | |
Swiss IBD Cohort Study Group, The |
Additional Credits
Journal
European journal of gastroenterology & hepatology
Publisher
Lippincott Williams & Wilkins
ISSN
0954-691X
Access(Rights)
metadata.only